CAS 55837-20-2|Halofuginone

Introduction:Basic information about CAS 55837-20-2|Halofuginone, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Common NameHalofuginone
CAS Number55837-20-2Molecular Weight414.681
Density1.7±0.1 g/cm3Boiling Point595.8±60.0 °C at 760 mmHg
Molecular FormulaC16H17BrClN3O3Melting Point>150ºC dec.
MSDS/Flash Point314.1±32.9 °C

Names

Name7-bromo-6-chloro-3-[3-[(2S,3R)-3-hydroxypiperidin-2-yl]-2-oxopropyl]quinazolin-4-one
SynonymMore Synonyms

Halofuginone BiologicalActivity

DescriptionHalofuginone (RU-19110) is a less-toxic form of Febrifugine, which is isolated from the plant Dichroa febrifuga[1]. Halofuginone inhibits prolyl-tRNA synthetase in an ATP-dependent manner with a Ki of 18.3 nM[2]. Halofuginone attenuates osteoarthritis (OA) by inhibition of TGF-β activity[3].
Related CatalogSignaling Pathways >>Cell Cycle/DNA Damage >>DNA/RNA SynthesisSignaling Pathways >>Stem Cell/Wnt >>TGF-beta/SmadSignaling Pathways >>TGF-beta/Smad >>TGF-beta/SmadResearch Areas >>Inflammation/ImmunologyNatural Products >>Alkaloid
Target

Ki: 18.3±0.5 nM (prolyl-tRNA synthetase)[2]

In VitroHalofuginone competitively inhibits prolyl-tRNA synthetase by occupying both the prolineand tRNA-binding pockets of prolyl-tRNA synthetase[1]. The IC50 of Halofuginone is 114.6 and 58.9 nM in KYSE70 and A549 cells. The IC50s of Halofuginone for NRF2 are 22.3 and 37.2 nM in KYSE70 and A549 cells, respectively. The IC50 of Halofuginone for global protein synthesis is 22.6 and 45.7 nM in KYSE70 and A549 cells, respectively[1]. The amount of NRF2 protein is significantly decreased in the presence of Halofuginone in both the KYSE70 and A549 cell lines. NRF2 mRNA levels are not decreased, but rather are increased after application of Halofuginone to both KYSE70 and A549 cells, indicating that Halofuginone acts to decrease NRF2 protein expression at the post-transcriptional level. Time-course studies show that Halofuginone decreases NRF2 protein expression in KYSE70 and A549 cells within 12 hours of treatment[1].
In VivoHalofuginone attenuates progression of OA in anterior cruciate ligament transection (ACLT) mice. The optimal dose (1 mg/kg body weight) is identified using multiple concentrations of HF (0.2, 0.5, 1 or 2.5 mg/kg) injected every other day for 1 month post surgery. Lower concentration (0.2 or 0.5 mg/kg) has minimal effects on subchondral bone and higher concentration (2.5 mg/kg) induces proteoglycan loss in articular cartilage[3]. Halofuginone (0.25-mg/kg, intraperitoneally) decreases NRF2 protein levels in tumors. While the tumor volumes do not change substantially between treatments with the vehicle, Halofuginone(0.25 mg/kg, intraperitoneally injected, every day) or cisplatin alone, combined treatment with Halofuginone and Cisplatin significantly suppresses the tumor volume compared to treatment with Halofuginone or cisplatin alone[1].
References

[1]. Tsuchida K, et al. Halofuginone enhances the chemo-sensitivity of cancer cells by suppressing NRF2 accumulation. Free Radic Biol Med. 2017 Feb;103:236-247.

[2]. Keller TL, et al. Halofuginone and other Febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat Chem Biol. 2012 Feb 12;8(3):311-7.

[3]. Cui Z, et al. Halofuginone attenuates osteoarthritis by inhibition of TGF-β activity and H-type vessel formation in subchondral bone. Ann Rheum Dis. 2016 Sep;75(9):1714-21.

Chemical & Physical Properties

Density1.7±0.1 g/cm3
Boiling Point595.8±60.0 °C at 760 mmHg
Melting Point>150ºC dec.
Molecular FormulaC16H17BrClN3O3
Molecular Weight414.681
Flash Point314.1±32.9 °C
Exact Mass413.014160
PSA84.22000
LogP1.24
Vapour Pressure0.0±1.8 mmHg at 25°C
Index of Refraction1.712
InChIKeyLVASCWIMLIKXLA-UHFFFAOYSA-N
SMILESO=C(CC1NCCCC1O)Cn1cnc2cc(Br)c(Cl)cc2c1=O
Storage condition-20°C

Synonyms

Halofuginone
empostatin
Halofuginonum
Halofuginona
Tempostatin
MFCD00866603
Stenorol
CAS 687636-93-7|2-Bromothiazole-5-methanol
CAS 32387-21-6|1-Methyl-1H-indole-3-carboxylic acid
Recommended......
TOP